R. Quarck

BMP9 Modulates IL-33 Signaling to Mitigate EndMT in Pulmonary Arterial Hypertension
20260 citationsauthor #3
Beta‐3 Adrenoreceptor Agonist Mirabegron Improves Right Ventricular Function in a Rat Monocrotaline‐Induced Pulmonary Hypertension Model
20260 citationsauthor #13
Circulating Pin1 Levels in Patients With Chronic Thromboembolic Pulmonary Hypertension: A Case‐Control Study
20250 citationsauthor #12
Distinct Morphological Types of Small Airway Obstructions in Smokers with Emphysema and End-Stage Chronic Obstructive Pulmonary Disease
20251 citationsauthor #25
Computational fluid dynamics of small airway disease in chronic obstructive pulmonary disease
20256 citationsauthor #24
Tricuspid Regurgitation and Pulmonary Haemodynamics After Pulmonary Endarterectomy.
20250 citationsauthor #3
MINIMALLY INVASIVE PULMONARY ENDARTERECTOMY THROUGH INVERTED-T UPPER HEMISTERNOTOMY
20250 citationsauthor #3
Consequences of the hemodynamic reclassification of pulmonary hypertension for chronic thromboembolic pulmonary disease.
20250 citationsauthor #7
Long-term effects of medical treatment in patients with chronic thromboembolic pulmonary hypertension
20251 citationsauthor #15
μCT Analysis of Microvascular Hemodynamics in PAH
20250 citationsauthor #11
Renal Outcomes After Lung or Combined Heart‐Lung Transplantation in Pulmonary Hypertension
20251 citationsauthor #4
Worldwide CTEPH Registry: Long-Term Outcomes With Pulmonary Endarterectomy, Balloon Pulmonary Angioplasty, and Medical Therapy
202440 citationsauthor #15
Angiogenesis in Chronic Thromboembolic Pulmonary Hypertension: A Janus-Faced Player?
20245 citationsauthor #7
Endothelial Features Along the Pulmonary Vascular Tree in Chronic Thromboembolic Pulmonary Hypertension: Distinctive or Shared Facets?
20243 citationsauthor #9
Pulmonary endarterectomy through inverted-T upper hemisternotomy
20242 citationsauthor #3
Corrigendum to ‘Pulmonary endarterectomy through inverted-T upper hemisternotomy’[JTCVS Techniques Volume 28, December 2024, Pages 65-72]
20240 citationsauthor #3
Plexiform lesions in human explant lungs with end-stage pulmonary arterial hypertension: µCT analysis
20240 citationsauthor #16
Pulmonary arterial hypertension drugs can partially restore altered angiogenic capacities in bmpr2‐silenced human lung microvascular endothelial cells
20231 citationsauthor #5
Impairment of Angiogenesis-Driven Clot Resolution Is a Key Event in the Progression to Chronic Thromboembolic Pulmonary Hypertension: Validation in a Novel Rabbit Model
20238 citationsauthor #1
Quantitative evaluation of pulmonary arteriolar structural changes in pulmonary arterial hypertension
20230 citationsauthor #26
Assessment of Small Airway Flow Parameters: A Comparative Study between Realistic and Idealistic Computational Models
20230 citationsauthor #17
Machine learning to differentiate pulmonary hypertension due to left heart disease from pulmonary arterial hypertension
20238 citationsauthor #8
Renal outcomes after lung and combined heart-lung transplantation in pulmonary hypertension
20230 citationsauthor #3
Using Families to Study Pulmonary Fibrosis Genetics
20230 citationsauthor #1
Small airway obstruction according to emphysema severity in human lungs
20231 citationsauthor #17
Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression
202286 citationsauthor #13
Health effects of exposure to residential air pollution in patients with pulmonary arterial hypertension: a cohort study in Belgium
20228 citationsauthor #6
A Comprehensive Assessment of Right Ventricular Function in Chronic Thromboembolic Pulmonary Hypertension
202217 citationsauthor #4
Genetic counselling and testing in pulmonary arterial hypertension: a consensus statement on behalf of the International Consortium for Genetic Studies in PAH
202238 citationsauthor #7
Disruption of GCN2 Pathway Aggravates Vascular and Parenchymal Remodeling During Pulmonary Fibrosis.
20229 citationsauthor #10
External validation of machine learning prediction model for pulmonary hypertension due to left heart disease
20220 citationsauthor #7
Renal outcomes according to baseline kidney function after lung or combined heart-lung transplantation for pulmonary hypertension
20220 citationsauthor #3
Outcomes After Lung or Combined Heart Lung Transplantation for PAH and CTEPH According to Baseline Kidney Function
20220 citationsauthor #3
Clinically applicable machine learning prediction model for pulmonary hypertension due to left heart disease
20211 citationsauthor #5
Incremental Experience in In Vitro Primary Culture of Human Pulmonary Arterial Endothelial Cells Harvested from Swan-Ganz Pulmonary Arterial Catheters
20215 citationsauthor #7
In vitro effects of vasodilatory drugs on BMPR2-silenced pulmonary microvascular endothelial cell function
20210 citationsauthor #5
PH CARE COVID survey: an international patient survey on the care for pulmonary hypertension patients during the early phase of the COVID-19 pandemic
202117 citationsauthor #4
Residential air pollution increases the risk for persistent pulmonary hypertension after pulmonary endarterectomy
20218 citationsauthor #6
Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH Registry
2021106 citationsauthor #15
Incremental experience in optimizing in vitro primary culture of human pulmonary arterial endothelial cells harvested from Swan-Ganz catheters
20210 citationsauthor #7
Kcnk3 Dysfunction Exaggerates The Development Of Pulmonary Hypertension Induced By Left Ventricular Pressure Overload.
202124 citationsauthor #10
GCN2 signalling is dysregulated in pulmonary fibrosis
20200 citationsauthor #7
COVID-19 in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a reference centre survey
202045 citationsauthor #2
Canagliflozin protects the vascular barrier during sepsis by AMPK dependant mechanisms
20201 citationsauthor #6
Risk assessment, therapy and cardiovascular comorbidity in patients with pulmonary arterial hypertension
20200 citationsauthor #3
Beta 3 adrenoceptor: a potential therapeutic target for pulmonary arterial hypertension
20201 citationsauthor #7
α1AMP-Activated Protein Kinase Protects against Lipopolysaccharide-Induced Endothelial Barrier Disruption via Junctional Reinforcement and Activation of the p38 MAPK/HSP27 Pathway
202012 citationsauthor #7
Cytokines trigger disruption of endothelium barrier function and p38 MAP kinase activation in BMPR2-silenced human lung microvascular endothelial cells
201918 citationsauthor #9
CCR2- and CCR5-Mediated Crosstalk Between Macrophages and Pulmonary-Artery Smooth Muscle Cells Drives Pulmonary Hypertension
20190 citationsauthor #14
Double‐lung versus heart‐lung transplantation for precapillary pulmonary arterial hypertension: a 24‐year single‐center retrospective study
201932 citationsauthor #21
CCR2/CCR5-mediated macrophage–smooth muscle cell crosstalk in pulmonary hypertension
2019111 citationsauthor #13
Learning from registries in pulmonary arterial hypertension: pitfalls and recommendations
201942 citationsauthor #2
Effect of outdoor air pollution on chronic thromboembolic pulmonary hypertension (CTEPH)
20190 citationsauthor #2
TGFβ and BMPRII signalling pathways in the pathogenesis of pulmonary arterial hypertension.
201980 citationsauthor #4
AMPK Protects against lps-induced endothelial hyperpermeability via activation of p38 mapk/hsp27 pathway and control of junctional proteins expression
20190 citationsauthor #3
Effect of BMPRII on endothelial function in human lung microvascular endothelial cells
20181 citationsauthor #8
Targeting CCR2 and CCR5 to inhibit macrophage/pulmonary artery smooth muscle cells cross-talk in pulmonary hypertension
20180 citationsauthor #10
Local inhibition of angiogenesis combined with repeated blood clot embolization induces chronic thromboembolic pulmonary hypertension in rabbits
20180 citationsauthor #1
Activation of the Beta-3 adrenoceptor in experimental pulmonary hypertension
20180 citationsauthor #3
Late Breaking Abstract - Development of an animal model for group 3 Pulmonary Hypertension
20181 citationsauthor #6
Administration of mitomycin results in pulmonary hypertension and vascular remodeling in rabbits
20171 citationsauthor #1
Rescuing BMPR2-driven endothelial dysfunction in PAH: a novel treatment strategy for the future?
201710 citationsauthor #1
Impact of insomnia on exercise capacity and quality of life in patients with pulmonary arterial hypertension
20171 citationsauthor #4
Progressive Vascular Functional and Structural Damage in a Bronchopulmonary Dysplasia Model in Preterm Rabbits Exposed to Hyperoxia
201636 citationsauthor #5
Role of interleukin-1 receptor 1/MyD88 signalling in the development and progression of pulmonary hypertension
201697 citationsauthor #9
BMPRII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators
201619 citationsauthor #10
Letter by Belge et al Regarding Article, "Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Models".
20163 citationsauthor #2
IL18 induces p38 MAP kinase activation and adhesion capacities in BMPRII knocked down human lung microvascular endothelial cells
20160 citationsauthor #9
Extracellular Calpain/Calpastatin Balance Is Involved in the Progression of Pulmonary Hypertension.
201618 citationsauthor #16
Osteopontin, a Key Mediator Expressed by Senescent Pulmonary Vascular Cells in Pulmonary Hypertension
201653 citationsauthor #19
signalingdysfunction by inhibiting LOX-1-mediated EGCG protects against oxidized LDL-induced
20150 citationsauthor #13
CARDIOVASCULAR, PULMONARY, AND RENAL PATHOLOGY Chemotherapy-Induced Pulmonary Hypertension Role of Alkylating Agents
20151 citationsauthor #3
See related Commentary on page 302 CARDIOVASCULAR , PULMONARY , AND RENAL PATHOLOGY Chemotherapy-Induced Pulmonary Hypertension Role of Alkylating Agents
2015182 citationsauthor #3
Contribution of inflammation and impaired angiogenesis to the pathobiology of chronic thromboembolic pulmonary hypertension
2015150 citationsauthor #1
Single center experience with systematic diagnostic and predictive genetic screening for pulmonary arterial hypertension
20140 citationsauthor #1
CCR5 as a Treatment Target in Pulmonary Arterial Hypertension
201480 citationsauthor #6
Is inflammation a potential therapeutic target in chronic thromboembolic pulmonary hypertension?
20144 citationsauthor #1
LSC 2014 abstract - Combined effects of inflammatory mediators and BMPR2 mutation on pulmonary arterial cell function in a pulmonary arterial hypertension
20141 citationsauthor #2
Measurement of right ventricular pressure by telemetry in conscious moving rabbits
20136 citationsauthor #3
Amorphous silica nanoparticles promote monocyte adhesion to human endothelial cells: size-dependent effect.
201339 citationsauthor #2
Ex vivo lung perfusion in pulmonary arterial hypertension lungs: concept and first human measurement
20130 citationsauthor #2
Repeated embolization and fibrinolysis inhibition induce chronic thromboembolic pulmonary hypertension in rabbits
20130 citationsauthor #1
Inflammatory mediators contribute to pulmonary arterial cell dysfunction in a pulmonary arterial hypertension patient with BMPR2 mutation
20130 citationsauthor #2
NF-κB pathway is involved in CRP-induced effects on pulmonary arterial endothelial cells in chronic thromboembolic pulmonary hypertension.
201346 citationsauthor #6
Characterization of proximal pulmonary arterial cells from chronic thromboembolic pulmonary hypertension patients
201249 citationsauthor #1
157 Platelet-Activating Factor Acetylhydrolase (PAF-AH): A Predictor of Adverse Event in Medically Treated CTEPH Patients?
20120 citationsauthor #1
Characterization of proximal pulmonary artery cells in chronic thromboembolic pulmonary hypertension patients
20120 citationsauthor #1
NFºB Pathway Is Involved In C-Reactive Protein-Induced Effects On Proximal Pulmonary Arterial Endothelial Cells Of CTEPH Patients
20120 citationsauthor #1
Effects of C-reactive protein on human pulmonary vascular cells in chronic thromboembolic pulmonary hypertension
201279 citationsauthor #2
PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE (PAF-AH): A PREDICTOR OF ADVERSE EVENT IN CTEPH PATIENTS?
20110 citationsauthor #1
Late-breaking abstract: Intracellular mechanisms behind the effect of C-reactive protein on proximal vascular cells of CTEPH patients
20110 citationsauthor #2
A Link Between Local And Systemic Inflammation At Advanced Stages Of Chronic Thromboembolic Pulmonary Hypertension
20112 citationsauthor #1
306 Is Inflammation Playing a Role in the Pathophysiology of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
20110 citationsauthor #1
Could platelet-activating factor acetylhydrolase (PAF-AH) predict adverse event in pulmonary hypertension?
20110 citationsauthor #1
Late-breaking abstract: Intracellular mechanisms behind the effect of C-reactive protein on proximal vascular cells of CTEPH patients
20110 citationsauthor #2
Pulmonary vascular cell dysfunction in chronic thromboembolic pulmonary hypertension: a role of c-reactive protein?
20100 citationsauthor #1
C-reactive Protein Contributes To Pulmonary Vascular Cell Dysfunction In Chronic Thromboembolic Pulmonary Hypertension
20100 citationsauthor #2
Role Of Endothelial And Smooth Muscle Cells In Vascular Wall Remodeling Of Large Pulmonary Arteries In Patients With CTEPH
20100 citationsauthor #1
Neutrophils stain positive for IL-17A in sputum of CF patients
20100 citationsauthor #2
Saturday, 17 July 2010
20100 citationsauthor #363

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT